TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study
For HCC patients with high tumor burden, HAIC demonstrates comparable efficacy to TACE-HAIC both in combination with TKIs and ICIs. Therefore, HAIC should be the preferred local therapeutic strategy over TACE-HAIC in HCC patients with high tumor burden.
Authors
- Chunxue Wu
- Xu Chang (ORCID: https://orcid.org/0000-0002-5825-0614)
- Xinge Li
- Guangshun Wang (ORCID: https://orcid.org/0000-0003-2769-3460)
- Huiyong Wu
- Yunlong Dong (ORCID: https://orcid.org/0000-0002-1730-4671)
- Wenbo Shao
Institutions
- Shandong Tumor Hospital (CN)
- Jinan Central Hospital (CN)
- Tianjin Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1664756
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97